Screener
Regenxbio RGNX Royalty Monetization Liabilities Noncurrent
Royalty Monetization Liabilities Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept rgnx:RoyaltyMonetizationLiabilitiesNoncurrent.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current liabilities | 82,621 | 118,095 |
| Deferred revenue | 15,404 | 18,943 |
| Operating lease liabilities | 61,596 | 65,215 |
| Royalty monetization liabilities | 154,746 | 147,408 |
| Other liabilities | 486 | 638 |
| Total liabilities | 314,853 | 350,299 |
| Stockholders’ equity | ||
| Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at June 30, 2026 and December 31, 2025 | — | — |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's royalty monetization liabilities noncurrent?
- Regenxbio (RGNX) reported royalty monetization liabilities noncurrent of $154.75M in Q2 2026.
- How has Regenxbio's royalty monetization liabilities noncurrent changed year-over-year?
- Regenxbio's royalty monetization liabilities noncurrent increased by 0.7% year-over-year, from $153.69M to $154.75M.
- What does royalty monetization liabilities noncurrent mean?
- Royalty Monetization Liabilities Noncurrent as reported by REGENXBIO Inc..
Ask your AI about Regenxbio's royalty monetization liabilities noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude